Cannabis Based Medicine

JAMA Neurology Publishes Results from Positive Phase 3 Trial of Epidiolex Oral Solution in Children with Seizures Associated with Dravet Syndrome

CARLSBAD, Calif., March 02, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that JAMA Neurology has published results from the second positive Phase 3 …

Read More »

Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 18, 2020 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the cannabinoids CBN (Cannabinol) and CBC (Cannabichromene) and their acidic form were shown to have necrotic effects on …

Read More »

Cannabics Pharmaceuticals Collaborates with RCKMC to Develop Cannabis Strains Targeting Gastrointestinal Cancers

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 11, 2020 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understanding with RCK Medical Cannabis to develop cannabis chemovars targeted to treat …

Read More »

Final Results of Cannabics’ Pilot Study of its Controlled Released Capsules for Treatment of Cancer Anorexia-Cachexia Syndrome Published

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 16, 2019 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the final results of its pilot study to test the efficacy of Cannabics’ Dosage-Controlled capsules for the treatment …

Read More »

Zynerba Announces Positive Data from its Phase 2 Study of its CBD Gel Zygel in Developmental and Epileptic Encephalopathies

DEVON, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced positive top line results from the open label Phase 2 BELIEVE 1 (Open Label Study to Assess the Safety and Efficacy of Zygel™ …

Read More »

GW Pharma Reports Positive Results from its Phase 3 Trial of Epidiolex in Patients with Seizures Associated with Tuberous Sclerosis Complex

CARLSBAD, Calif., May 06, 2019 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase …

Read More »

INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis

PHOENIX, Jan. 09, 2019 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the results of a dose-finding pharmacokinetic (PK) study (INS015-18-124) of its epinephrine nasal spray. These results identified a dose that showed a …

Read More »

Insys Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy

PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) — Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, was generally well-tolerated—even at high doses—as an investigational treatment for refractory pediatric epilepsy, according to new clinical …

Read More »

Cannabics Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 16, 2018 /PRNewswire/ —  Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today the results of its pilot study to test the efficacy of Cannabics capsules for the treatment of cancer anorexia-cachexia …

Read More »

DEA Reschedules GW Pharma’s Epidiolex (cannabidiol) Oral Solution to Schedule V

LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral …

Read More »